Unveiling the Potential Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Offering Protection of the Cardiovascular, Renal, and Neural Systems: An Updated Narrative Review.
揭示胰高血糖素樣肽-1 (GLP-1) 受體激動劑在保護心血管、腎臟和神經系統中的潛在作用:更新的敘述性綜述。
Cureus 2024-09-02
HOW did GLP-1RAs bring about a paradigm shift in the guidelines of managing T2DM: A path to gluco-cardio Centricity.
GLP-1RAs 如何在管理T2DM的指引中帶來範式轉變:通往葡萄糖心臟中心的道路。
Indian Heart J 2023-03-08
Role of GLP-1 Receptor Agonist in Diabetic Cardio-renal Disorder: Recent Updates of Clinical and Pre-clinical Evidence.
GLP-1 受體激動劑在糖尿病心腎疾病中的作用:臨床和臨床前證據的最新更新。
Curr Diabetes Rev 2024-05-13
Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Cardiovascular Risk Management in Patients With Type 2 Diabetes Mellitus: A Systematic Review.
GLP-1受體激動劑在第2型糖尿病患者心血管風險管理中的作用:系統性回顧。
Cureus 2023-10-21
Cardiovascular Protective Properties of GLP-1 Receptor Agonists: More than Just Diabetic and Weight Loss Drugs.
GLP-1 受體激動劑的心血管保護特性:不僅僅是糖尿病和減重藥物。
J Clin Med 2024-08-29
Assessing the therapeutic and toxicological profile of novel GLP-1 receptor agonists for type 2 diabetes.
評估新型 GLP-1 受體激動劑在 2 型糖尿病中的治療和毒理特徵。
Expert Opin Drug Metab Toxicol 2024-09-13